Talk:Tumor antigen

	This article is within the scope of WikiProject Molecular Biology, a collaborative effort to improve the coverage of Molecular Biology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Molecular BiologyWikipedia:WikiProject Molecular BiologyTemplate:WikiProject Molecular BiologyMolecular Biology articles
???	This article has not yet received a rating on the importance scale.
	This article is supported by the Molecular and Cell Biology task force (assessed as Low-importance).

Medicine Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Low	This article has been rated as Low-importance on the project's importance scale.

Tumor antigen vs. tumor marker[edit]

Please note that tumor antigen is different from tumor marker. Some tumor antigens can be used as tumor markers but the primary feature of tumor antigens is their immunogenecity whereas the primary feature of tumor markers is easy estimation / detectability so that they can be used for screening or as prognostic indicators. So please do not merge the two articles. - TwoOars (Rev) 20:43, 28 September 2007 (UTC)[reply]

Direct injection of adjuvants?[edit]

As a general question, why is there so much focus on developing specific tumor antigens, rather than developing adjuvants that might be directed into tumors in situ? We know the antigens are present in tumors already, often vary between patients, and tend to be expensive, whereas adjuvants could potentially be a very cheap treatment. I would think that if a battery of noxious substances like Freund's Complete Adjuvant or urushiols were tested by direct injection into tumors there would be at least some possibility that one of them might stimulate an immune response against extracellular antigens, but it doesn't seem like the idea is being pursued. Mike Serfas 13:56, 29 September 2007 (UTC)[reply]

You might be interested some recent work on implants that contain adjuvants and antigens together. I could imagine implanting one without added antigens into a tumor, in cases where no antigen is known.--128.115.27.11 (talk) 21:51, 2 February 2009 (UTC)[reply]

WikiProject class rating[edit]

This article was automatically assessed because at least one WikiProject had rated the article as start, and the rating on other projects was brought up to start class. BetacommandBot 16:32, 10 November 2007 (UTC)[reply]

Discover via antibody[edit]

Sometimes the antigen is only known by the antibody that binds to it. eg the MX35 mAb was developed by 1987 but it was only in 2008 that the protein that included the epitope was identified. See MX35. Not sure if this situation is frequent enough to mention in this article. - Rod57 (talk) 14:29, 7 November 2016 (UTC)[reply]

Metion "neoantigen"[edit]

Neoantigen currently redirects to this article. After a bit of searching, I'm really confused on the delineation between the word "neoantigen" and the term "tumor specific antigen". My suspision is that these things are basically synonomous, and that "neoantigen" became popularized around 2014. I think the article should mention "neoantigens" somewhere, but I'm not sure how to include it. NickCT (talk) 13:58, 10 July 2023 (UTC)[reply]